|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

,
Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK
Correspondence
Ervin Fodor
ervin.fodor{at}path.ox.ac.uk
| ABSTRACT |
|---|
|
|
|---|
These authors contributed equally to this work. ![]()
Present address: Department of Virology, Imperial College London, St Mary's Hospital, Norfolk Place, London W2 1PG, UK. ![]()
Two supplementary tables of primer sequences are available with the online version of this paper.
| INTRODUCTION |
|---|
|
|
|---|
The eighth vRNA segment of the influenza A virus directs the synthesis of two mRNAs. The first of these encodes the non-structural (NS) protein, NS1, while the other is derived from splicing of the NS1 mRNA and is translated into a protein of 121 aa (Lamb & Lai, 1980
). This protein localizes to the cell nucleus and was originally named NS2 (Inglis et al., 1979
; Lamb & Choppin, 1979
). However, it was demonstrated later that NS2 is present in purified virions, where it interacts with the virus matrix (M1) protein (Richardson & Akkina, 1991
; Yasuda et al., 1993
). Both M1 and NS2 are directly involved in the nuclear export of vRNPs during the viral life cycle, therefore it has been proposed that NS2 be renamed the nuclear export protein (NEP) (O'Neill et al., 1998
). The nuclear export of vRNPs is carried out by the cellular export protein Crm1 (Elton et al., 2001
) and there is evidence that NS2/NEP mediates the association between the two. The current model involves an export complex in which NS2/NEP has an N-terminal association with Crm1 and a C-terminal association with the viral M1 protein, which in turn is bound to vRNPs (Akarsu et al., 2003
). The NS2/NEP protein also binds several nucleoporins and is thought to be responsible for recruiting the export machinery and directing the export of the complex (O'Neill et al., 1998
).
In addition to the role of NS2/NEP in the export of vRNPs, it has been shown that a point mutation at position 32 in the NS2/NEP protein of the A/WSN/33 influenza virus Wa-182 results in the production of defective interfering (DI) particles lacking an intact PA gene after a single high-multiplicity cycle of infection (Odagiri & Tobita, 1990
; Odagiri et al., 1994
). Furthermore, a study in which an influenza A chloramphenicol acetyltransferase (CAT) reporter gene was used to assess RNA synthesis showed that the NS2/NEP protein inhibited RNA synthesis by reducing the levels of vRNA, cRNA and mRNA (Bullido et al., 2001
).
The eighth vRNA segment of the influenza B virus genome also encodes both NS1 and NS2/NEP proteins, although less is known about the function of NS2/NEP in influenza B viruses compared with type A viruses. There is evidence that the protein plays a role in vRNP export (Paragas et al., 2001
), although it has been suggested that the complex formation between NS2/NEP, M1 and the vRNPs of influenza B is different from that of influenza A, in that the type B NS2 protein associates directly with vRNPs independently of M1 (Imai et al., 2003
).
In this study, we investigated the effect of the NS2/NEP protein on viral transcription and replication by using ribonucleoprotein (RNP) reconstitution assays. We found that co-expression of NS2/NEP affects viral RNA levels, resulting in reduced accumulation of transcription products and an increase in the accumulation of viral replication products. This property of NS2/NEP appears to be independent of its previously suggested function in vRNP export. Therefore, we propose a second role for the influenza NS2/NEP protein during the viral life cycle in the regulation of viral transcription and replication.
| METHODS |
|---|
|
|
|---|
Plasmids.
The protein expression plasmids pcDNA-PB1, pcDNA-PB2, pcDNA-PA, pcDNA-NP and pcDNA-3A have been described previously (Fodor et al., 2002
), as have the pPOLI-PB1-RT, pPOLI-PB2-RT, pPOLI-PA-RT, pPOLI-HA-RT, pPOLI-NP-RT, pPOLI-NA-RT, pPOLI-M-RT and pPOLI-NS-RT vRNA transcription plasmids (Fodor et al., 1999
). To generate the pPOLI-NS1-RT plasmid, site-directed mutagenesis was carried out on the pPOLI-NS-RT plasmid, whereby a stop codon was introduced into the NS2 ORF after 15 aa residues and 2 nt mutations were introduced into the acceptor splice site. These plasmids have coding sequences derived from the A/WSN/33 virus. The pcDNA-NS2 (A/WSN) plasmid was constructed by PCR amplifying the NS2 ORF using pPOLI-NS-RT as template (primers 5'-ATATGAATTCATAATGGATCCAAACACTGTGTCAAGCTTTCAGGACATACTGATGAGGATGT-3' and 5'-ATGCCTCGAGTTAAATAAGCTGAAACGAGA-3'). The PCR product was digested with EcoRI and XhoI and cloned into pcDNA-3A digested with the same restriction enzymes. The pcDNA-NS2 (A/Vic) and pcDNA-NS2 (B/Beij) plasmids containing the NS2 protein ORFs from the A/Victoria/3/75 and B/Beijing/1/87 viruses, respectively, were constructed using a similar strategy. The pcDNA-TAP-NS2 plasmid was created by replacing the CTD sequence in the pcDNA-TAP-CTD construct (Engelhardt et al., 2005
), using the NotI and XbaI restriction sites, with the NS2 ORF PCR-amplified from pcDNA-NS2 (A/WSN). The 53–121, 1–53, 21–121 and 1–90 NS2 deletion mutants were constructed by PCR amplification of the pcDNA-TAP-NS2 template (primers given in Supplementary Table S1, available in JGV Online). Following amplification, 53–121 and 21–121 PCR products were digested with NotI and self-ligated, and 1–53 and 1–90 were digested with XhoI and cloned into pcDNA-TAP-NS2 digested with the same restriction enzyme. All constructs were confirmed by sequencing and protein expression was confirmed by Western blot analysis. Plasmids encoding influenza B virus sequences were kindly provided by Wendy Barclay (Imperial College, London) and have been described previously (Jackson et al., 2002
). The pCIPB1, pCIPB2, pCIPA and pCINP plasmids express RNA polymerase subunits and NP of the influenza B/Panama/45/90 virus, while the pPRPA and pPRNA plasmids express PA and NA vRNA, respectively, of the influenza B/Beijing/1/87 virus.
Transfections and infections.
Transfections for RNP reconstitution assays were performed in human kidney 293T cells in suspension in 35 mm dishes (approx. 106 cells) by using 10 µl Lipofectamine 2000 (Invitrogen) and 1 µg of each of the relevant plasmids in 1.5 ml MEM with 10 % FCS. Cells were harvested 48 h post-transfection (p.t.) or at the time points indicated. Human kidney 293T cells were infected with A/WSN/33 virus at an m.o.i. of either 2.5 or 10 in a total of 1 ml MEM with 0.5 % FCS per 35 mm dish. Cells were harvested at the time points indicated. Where required, cells were treated with 5 µg actinomycin D ml–1 at 37 °C for 1 h at 22 h p.t. and then infected with A/WSN/33 virus at an m.o.i. of 10. Cells were harvested at 4 h post-infection (p.i.).
RNA isolation and primer extension analysis.
Total RNA was extracted from 293T cells in 35 mm dishes using 1 ml TRIzol Reagent (Invitrogen). 1/30th of each of the RNA samples was analysed by primer extension. RNA was mixed with an excess of two 32P-labelled DNA primers in 5 µl and denatured by heating at 95 °C for 3 min. The mixture was cooled on ice and transferred to 45 °C for 2 min prior to the addition of 5 µl 2x transcription mix [2x First Strand Buffer (Invitrogen), 20 mM DTT, 1 mM dNTP mix and 50 U SuperScript II RNase H– reverse transcriptase (Invitrogen)] also heated to 45 °C. The reaction was stopped after 1 h by the addition of 8 µl 90 % formamide, and heating at 95 °C for 3 min. Transcription products were analysed on 6 % polyacrylamide gels containing 7 M urea in TBE buffer and detected by autoradiography. The viral-gene-specific primers used are given in Supplementary Table S2, available in JGV Online. A primer detecting cellular 5S rRNA (5'-TCCCAGGCGGTCTCCCATCC-3') was included as an internal control where required.
Western blotting.
Cell lysates were analysed by SDS-PAGE followed by Western blotting. The antibodies used were anti-NS2 (Akarsu et al., 2003
) and anti-rabbit horseradish peroxidase-conjugated IgG (Sigma); these were detected using an Immobilon chemiluminescent Western detection kit (Millipore).
| RESULTS |
|---|
|
|
|---|
|
|
|
The effect of NS2/NEP on the accumulation of viral transcription and replication products is functionally conserved in influenza B viruses
An alignment of the amino acid sequence of the A/WSN/33 and B/Beijing/1/87 virus NS2/NEP proteins shows that there is only 22 % identity between the two (Fig. 4a
). Nonetheless, when the B/Beijing/1/87 NS2/NEP protein was co-expressed in an influenza B RNP reconstitution assay, a decrease in the accumulation of mRNA and an increase in the accumulation of cRNA, an effect similar to that in influenza A RNP reconstitution, was observed for both the NA and PA gene segments (Fig. 4b
). No effect on the accumulation of vRNA was observed. The ability of the NS2/NEP protein to downregulate mRNA and upregulate cRNA accumulation appears to be functionally conserved between influenza A and B viruses.
|
The effect of NS2/NEP on viral RNA levels is independent of M1 expression
The current model of vRNP nucleocytoplasmic export involves an export complex in which NS2/NEP has an N-terminal association with Crm1 and a C-terminal association with M1, which in turn is bound to vRNPs (Akarsu et al., 2003
). We performed RNP reconstitution assays in which NS2/NEP alone or both NS2/NEP and the M1 protein were co-expressed (Fig. 5a
). The expression of M1 was confirmed by Western blot analysis (data not shown). The effect of NS2/NEP on viral RNA levels of the PA segment was similar in both the presence and absence of M1, as a significant decrease in mRNA and increase in cRNA was observed in both cases (Fig. 5b
). Similar results were obtained for the PB1, PB2 and NA segments (data not shown). The NS2/NEP protein therefore has the ability to regulate viral replication and transcription independently of M1 expression.
|
The nuclear export sequence (NES) of NS2/NEP is not required for its regulatory activity
In order to gain further information about the role of NS2/NEP in the regulation of transcription and replication, a number of NS2/NEP deletion mutants were constructed, including C-terminal and N-terminal fragments and proteins lacking either NES or the C2 alpha-helical structure of the C terminus (Fig. 6a
). The deletion mutants were made using a pcDNA-TAP-NS2 protein-expression plasmid. The presence of the tag does not interfere with the ability of NS2/NEP to affect viral RNA levels in RNP reconstitution assays (data not shown). Expression of the mutant NS2/NEP proteins was verified by Western blot analysis (Fig. 6b
) and shown to be similar to wild-type levels, with the exception of the NS2 1–90 construct that has slightly reduced protein expression. The localization of the NEP/NS2 deletion mutants was analysed by immunofluorescence. Preliminary data revealed no obvious differences in the localization pattern of the deletion mutants compared with the wild type (data not shown). The effect of mutant NS2/NEP proteins was tested in RNP reconstitution, followed by the analysis of viral RNAs of the PA gene segment (Fig. 6c
). Viral RNA levels from three independent experiments were quantified and compared with values obtained in the absence of NS2/NEP, which were set as 100 % (Fig. 6d
).
|
The NS2 21–121 mutant was the only protein to produce a significant decrease in mRNA similar to that produced by the wild-type protein (Fig. 6d
). NS2 21–121 shows both a significant decrease in mRNA and an increase in cRNA levels, indicating that almost the full-length protein is required for an effect on both transcription and replication. As the C-terminal fragment alone (NS2 53–121) cannot cause a significant decrease in mRNA levels, the region located between aa 21 and 53 of the protein appears to be important for its effect on mRNA. This region alone cannot produce a decrease in mRNA levels, however, as demonstrated by the NS2 1–53 and NS2 1–90 constructs. Therefore, in order to produce an effect on both mRNA and cRNA, both the C2 alpha-helical region, located between aa 94 and 115, and region 21–53 of the N terminus of the NS2/NEP protein are required.
NS2 21–121 has the ability to affect viral mRNA and cRNA levels despite lacking the NES region located between aa 12 and 21 which has been implicated in Crm1 binding and shown to be vital for vRNP export (Neumann et al., 2000
). We therefore conclude that the NES region of NS2/NEP is not required for the regulation of transcription and replication and that this activity of NS2/NEP is likely to be independent of its transport function.
| DISCUSSION |
|---|
|
|
|---|
The effect of NS2/NEP on RNA levels is influenza-virus-type-specific; influenza A virus NS2/NEP affects influenza A RNPs, while influenza B virus NS2/NEP has a regulatory effect on influenza B RNPs, but neither affects the other type. The regulation by NS2/NEP occurs independently of M1 expression and is not affected by deletion of the NES region that has been shown to be important for the nuclear export function of NS2/NEP. We therefore propose that NS2/NEP has multiple roles during the influenza virus life cycle: in addition to its previously described role in vRNP export, the protein also functions in a regulatory capacity. This regulation is likely to be a critical requirement for the viral life cycle, as it is conserved in both influenza A and B viruses.
At this time, we can only speculate on how NS2/NEP mediates its effect on the accumulation of viral RNAs. As the regulatory effect is influenza-virus-type specific, it is unlikely that NS2/NEP would mediate its effect indirectly by affecting the host cell; it is more likely that NS2/NEP mediates its activity via a direct interaction with the components of the vRNPs. Indeed, the influenza type B and type C NS2/NEP proteins have been shown to associate directly with the vRNP complex (Paragas et al., 2001
; Kohno et al., 2009
). We have performed co-purification and co-immunoprecipitation assays to investigate the possibility of an interaction between NS2/NEP and the components of influenza type A vRNPs but, in agreement with others (O'Neill et al., 1998
; Imai et al., 2003
), no interaction could be detected (data not shown). However, the possibility of a weak or transient interaction cannot be ruled out. In fact, the atypical decrease in vRNA levels observed for the NP gene when NS2/NEP is expressed (Fig. 3a and b
) is suggestive of a possible role for NP. The conserved chemical nature of the amino acid residues between influenza type A and B NS2/NEP proteins suggests a common tertiary structure (Akarsu et al., 2003
), which supports the hypothesis that both type A and B NS2/NEP proteins are mediating the regulation of transcription and replication in a similar way.
Our results do not distinguish whether NS2/NEP has an effect on the synthesis of RNAs or on their stability. According to one possible scenario, binding of NS2/NEP to vRNPs (and possibly cRNPs) inhibits their ability to act as templates for both transcription and replication. This would inevitably lead to a reduction in the accumulation of viral mRNA levels, as observed in our experiments. It could also lead to the observed increase in the accumulation of cRNA/vRNA levels if we postulate that transcriptionally inactive RNPs are more stable as they are less likely to be subject to degradation by nucleases. During transcription, RNPs must unfold to some degree to allow transcription by the RNA polymerase; this may increase the accessibility of the RNA to nucleases, resulting in a greater degree of degradation. Intriguingly, there seems to be little, if any, correlation between the increase of cRNA and vRNA levels for the different gene segments analysed (see Fig. 3b
). This might indicate that NS2/NEP could indeed act via the stabilization of RNPs, resulting in transcriptionally inactive forms. There are many possible explanations for why NS2/NEP may do this; one possibility is that by binding to RNPs, NS2/NEP, known to accumulate in the nucleus of cells late in infection, could induce an RNP conformation that destines RNPs for packaging, rather than acting as templates for transcription and replication.
It is unlikely that the regulatory function of NS2/NEP is directly related to vRNP export. Mutation of a tryptophan at residue 78 in the C terminus of the NS2/NEP protein, previously demonstrated to be critical for binding to M1 (Akarsu et al., 2003
), did not affect the ability of NS2/NEP to regulate viral RNA levels (data not shown). In addition, fractionation experiments showed that the nuclear and cytoplasmic localization of viral RNA species was not altered by NS2/NEP and leptomycin B, an inhibitor of Crm1, did not alter the effect of NS2/NEP (data not shown).
In a previous study, it was suggested that the NS2/NEP protein inhibits RNA synthesis by reducing the levels of vRNA, cRNA and mRNA (Bullido et al., 2001
). Although this study does suggest a regulatory role for NS2/NEP, the results do not correlate entirely with our own results where only mRNA levels were reduced and cRNA levels were in fact increased. The effect observed by Bullido et al. (2001)
was strictly dependent on the expression levels of NS2/NEP. We have therefore carried out experiments to address the question of how increasing amounts of NS2/NEP affect the accumulation of viral RNAs. We have found that the effect on viral RNA levels becomes more pronounced if more NEP/NS2 protein is expressed, i.e. a stronger decrease in the accumulation of mRNA and a stronger increase in the accumulation of cRNA is observed (data not shown). We have also confirmed that the expression levels of NS2/NEP in the RNP reconstitution system used here were comparable to those in viral infection (results not shown). We suggest that the differences between the two studies may be explained by the vaccinia helper virus system used in the previous experiments, which may itself affect influenza virus replication or the host cell.
In summary, we have shown that regulation of transcription and replication during viral infection and in RNP reconstitution assays differ. We have found that the co-expression of NS2/NEP affects the accumulation of viral RNAs in RNP reconstitutions, suggesting a novel regulatory function for NS2/NEP. We therefore propose that the NS2/NEP protein plays a role in the regulation of viral transcription and replication during the viral life cycle.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Baudin, F., Petit, I., Weissenhorn, W. & Ruigrok, R. W. (2001). In vitro dissection of the membrane and RNP binding activities of influenza virus M1 protein. Virology 281, 102–108.[CrossRef][Medline]
Braam, J., Ulmanen, I. & Krug, R. M. (1983). Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell 34, 609–618.[Medline]
Bullido, R., Gómez-Puertas, P., Saiz, M. J. & Portela, A. (2001). Influenza A virus NEP (NS2 protein) downregulates RNA synthesis of model template RNAs. J Virol 75, 4912–4917.
Deng, T., Vreede, F. T. & Brownlee, G. G. (2006). Different de novo initiation strategies are used by influenza virus RNA polymerase on its cRNA and viral RNA promoters during viral RNA replication. J Virol 80, 2337–2348.
Elster, C., Larsen, K., Gagnon, J., Ruigrok, R. W. & Baudin, F. (1997). Influenza virus M1 protein binds to RNA through its nuclear localization signal. J Gen Virol 78, 1589–1596.[Abstract]
Elton, D., Simpson-Holley, M., Archer, K., Medcalf, L., Hallam, R., McCauley, J. & Digard, P. (2001). Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol 75, 408–419.
Engelhardt, O. G., Smith, M. & Fodor, E. (2005). Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II. J Virol 79, 5812–5818.
Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G. & García-Sastre, A. (1999). Rescue of influenza A virus from recombinant DNA. J Virol 73, 9679–9682.
Fodor, E., Crow, M., Mingay, L. J., Deng, T., Sharps, J., Fechter, P. & Brownlee, G. G. (2002). A single amino acid mutation in the PA subunit of the influenza virus RNA polymerase inhibits endonucleolytic cleavage of capped RNAs. J Virol 76, 8989–9001.
Gabriel, G., Dauber, B., Wolff, T., Planz, O., Klenk, H. D. & Stech, J. (2005). The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S A 102, 18590–18595.
Imai, M., Watanabe, S. & Odagiri, T. (2003). Influenza B virus NS2, a nuclear export protein, directly associates with the viral ribonucleoprotein complex. Arch Virol 148, 1873–1884.[CrossRef][Medline]
Inglis, S. C., Barrett, T., Brown, C. M. & Almond, J. W. (1979). The smallest genome RNA segment of influenza virus contains two genes that may overlap. Proc Natl Acad Sci U S A 76, 3790–3794.
Jackson, D., Cadman, A., Zurcher, T. & Barclay, W. S. (2002). A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J Virol 76, 11744–11747.
Kohno, Y., Muraki, Y., Matsuzaki, Y., Takashita, E., Sugawara, K. & Hongo, S. (2009). Intracellular localization of influenza C virus NS2 protein (NEP) in infected cells and its incorporation into virions. Arch Virol 154, 235–243.[CrossRef][Medline]
Krug, R. M. (1981). Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr Top Microbiol Immunol 93, 125–149.[Medline]
Labadie, K., Dos Santos Afonso, E., Rameix-Welti, M. A., van der Werf, S. & Naffakh, N. (2007). Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells. Virology 362, 271–282.[CrossRef][Medline]
Lamb, R. A. & Choppin, P. W. (1979). Segment 8 of the influenza virus genome is unique in coding for two polypeptides. Proc Natl Acad Sci U S A 76, 4908–4912.
Lamb, R. A. & Lai, C. J. (1980). Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of influenza virus. Cell 21, 475–485.[CrossRef][Medline]
Lee, K. H. & Seong, B. L. (1998). The position 4 nucleotide at the 3' end of the influenza virus neuraminidase vRNA is involved in temporal regulation of transcription and replication of neuraminidase RNAs and affects the repertoire of influenza virus surface antigens. J Gen Virol 79, 1923–1934.[Abstract]
Lee, M. K., Bae, S. H., Park, C. J., Cheong, H. K., Cheong, C. & Choi, B. S. (2003). A single-nucleotide natural variation (U4 to C4) in an influenza A virus promoter exhibits a large structural change: implications for differential viral RNA synthesis by RNA-dependent RNA polymerase. Nucleic Acids Res 31, 1216–1223.
Mullin, A. E., Dalton, R. M., Amorim, M. J., Elton, D. & Digard, P. (2004). Increased amounts of the influenza virus nucleoprotein do not promote higher levels of viral genome replication. J Gen Virol 85, 3689–3698.
Neumann, G., Hughes, M. T. & Kawaoka, Y. (2000). Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J 19, 6751–6758.[CrossRef][Medline]
Odagiri, T. & Tobita, K. (1990). Mutation in NS2, a nonstructural protein of influenza A virus, extragenically causes aberrant replication and expression of the PA gene and leads to generation of defective interfering particles. Proc Natl Acad Sci U S A 87, 5988–5992.
Odagiri, T., Tominaga, K., Tobita, K. & Ohta, S. (1994). An amino acid change in the non-structural NS2 protein of an influenza A virus mutant is responsible for the generation of defective interfering (DI) particles by amplifying DI RNAs and suppressing complementary RNA synthesis. J Gen Virol 75, 43–53.
O'Neill, R. E., Talon, J. & Palese, P. (1998). The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 17, 288–296.[CrossRef][Medline]
Palese, P. (1977). The genes of influenza virus. Cell 10, 1–10.[CrossRef][Medline]
Paragas, J., Talon, J., O'Neill, R. E., Anderson, D. K., García-Sastre, A. & Palese, P. (2001). Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. J Virol 75, 7375–7383.
Pleschka, S., Jaskunas, R., Engelhardt, O. G., Zurcher, T., Palese, P. & García-Sastre, A. (1996). A plasmid-based reverse genetics system for influenza A virus. J Virol 70, 4188–4192.[Abstract]
Portela, A. & Digard, P. (2002). The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 83, 723–734.
Richardson, J. C. & Akkina, R. K. (1991). NS2 protein of influenza virus is found in purified virus and phosphorylated in infected cells. Arch Virol 116, 69–80.[CrossRef][Medline]
Salomon, R., Franks, J., Govorkova, E. A., Ilyushina, N. A., Yen, H. L., Hulse-Post, D. J., Humberd, J., Trichet, M., Rehg, J. E. & other authors (2006). The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med 203, 689–697.
Vreede, F. T., Jung, T. E. & Brownlee, G. G. (2004). Model suggesting that replication of influenza virus is regulated by stabilization of replicative intermediates. J Virol 78, 9568–9572.
Watanabe, K., Handa, H., Mizumoto, K. & Nagata, K. (1996). Mechanism for inhibition of influenza virus RNA polymerase activity by matrix protein. J Virol 70, 241–247.[Abstract]
Yasuda, J., Nakada, S., Kato, A., Toyoda, T. & Ishihama, A. (1993). Molecular assembly of influenza virus: association of the NS2 protein with virion matrix. Virology 196, 249–255.[CrossRef][Medline]
Ye, Z. P., Pal, R., Fox, J. W. & Wagner, R. R. (1987). Functional and antigenic domains of the matrix (M1) protein of influenza A virus. J Virol 61, 239–246.
Ye, Z. P., Baylor, N. W. & Wagner, R. R. (1989). Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol 63, 3586–3594.
Received 12 December 2008;
accepted 21 February 2009.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |